Mark Levstik
Overview
Explore the profile of Mark Levstik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
529
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ruffolo L, Levstik M, Boehly J, Spiro M, Raptis D, Liu L, et al.
Clin Transplant
. 2022 Apr;
36(10):e14688.
PMID: 35468241
Background: Deep venous thrombosis (DVT) prophylaxis is often employed to prevent the potentially serious complication of pulmonary embolism (PE). However, little data exist regarding the optimal DVT prophylaxis strategy for...
2.
Bell P, Thung S, Weiss S, Levstik M, Zhang D, Liu X, et al.
Pathol Res Pract
. 2019 Dec;
216(2):152770.
PMID: 31810588
Hepatocellular adenoma (HCA) is a rare benign tumor of the liver with low risk of malignant transformation. It is associated with oral contraceptives/anabolic steroid use, metabolic disease, and rarely, vascular...
3.
Tun-Abraham M, Wanis K, Garcia-Ochoa C, Sela N, Sharma H, Al Hasan I, et al.
Can J Surg
. 2018 Nov;
62(1):44-51.
PMID: 30484989
Background: Outcomes in liver transplantation with organs obtained via donation after cardiocirculatory death (DCD) have been suboptimal compared to donation after brain death, attributed mainly to the high incidence of...
4.
Dulaney D, Dokus K, McIntosh S, Al-Judaibi B, Ramaraju G, Tomiyama K, et al.
J Gastrointest Surg
. 2017 Aug;
21(10):1643-1649.
PMID: 28785937
Purpose: Biliary complications following liver transplantation are a significant source of morbidity, potentially leading to graft failure necessitating retransplantation. We sought to evaluate smoking as an independent risk factor for...
5.
Wells M, Roth L, Marotta P, Levstik M, Mason A, Bain V, et al.
Saudi J Gastroenterol
. 2013 Sep;
19(5):223-9.
PMID: 24045596
Background/aim: In patients with advanced post-transplant hepatitis C virus (HCV) recurrence, antiviral treatment (AVT) with interferon and ribavirin is indicated to prevent graft failure. The aim of this study was...
6.
Lingard L, McDougall A, Levstik M, Chandok N, Spafford M, Schryer C
Med Educ
. 2012 Aug;
46(9):869-77.
PMID: 22891907
Objectives: In order to be relevant and impactful, our research into health care teamwork needs to better reflect the complexity inherent to this area. This study explored the complexity of...
7.
Myers R, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, et al.
Liver Int
. 2012 Mar;
32(6):902-10.
PMID: 22435761
Background: Accurate tools for the noninvasive detection of hepatic steatosis are needed. The Controlled Attenuation Parameter (CAP) specifically targets liver steatosis using a process based on transient elastography. Methods: Patients...
8.
Myers R, Pomier-Layrargues G, Kirsch R, Pollett A, Beaton M, Levstik M, et al.
J Hepatol
. 2011 Oct;
56(3):564-70.
PMID: 22027584
Background & Aims: The FibroScan XL probe facilitates liver stiffness measurement (LSM) by transient elastography (TE) in obese patients, yet factors affecting its accuracy have not been described. Our objectives...
9.
Levstik M, Wong P, Greanya E, Yoshida E
Ann Hepatol
. 2011 Sep;
10(4):441-4.
PMID: 21911883
Introduction: Hepatitis B virus (HBV) related liver transplant (LT) recipients face a high risk of HBV reinfection in the absence of continuous post-operative HBV prophylaxis. Combination HBV prophylaxis with hepatitis...
10.
Myers R, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, et al.
Hepatology
. 2011 Sep;
55(1):199-208.
PMID: 21898479
Unlabelled: Failure of liver stiffness measurement (LSM) by transient elastography (TE, FibroScan) and unreliable results occur in ≈ 5% and 15% of patients, respectively, mainly due to obesity. In this...